Abstract
Previous studies showed a link between systemic lupus erythematosus (SLE) and Epstein-Barr virus (EBV) infection. We sought to determine the features of serologic response to EBV in SLE patients and whether this response differs from those of systemic sclerosis (SSc) and primary antiphospholipid syndrome (PAPS) patients as well as healthy individuals. Sera from 198 consecutive SLE patients have been tested to detect IgG antibodies to EA/D, EBNA-1, VCA P18 and for comparison, cytomegalovirus (CMV) using commercially available ELISA kits (Trinity Biotech, USA). Forty-six SSc patients and 38 PAPS patients were enrolled as diseased control groups and sixty-five individuals as healthy controls. Significantly more SLE (54%, P = 0.001, OR 5.77, 95% CI 2.8–11.6), SSc (41.3%, P = 0.005, OR 3.4, 95% CI 1.4–8.2) and PAPS sera (36.8%, P = 0.023, OR 2.86, 95% CI 1.14–7.22) reacted against EA/D than healthy controls (16.9%). The mean age of anti-EA/D-positive SLE patients was significantly higher, and their disease duration was longer compared to anti-EA/D-negative SLE patients (41 ± 14 vs. 33.8 ± 10.8 years, P < 0.001 and 100 ± 73 vs. 71 ± 62 months, P = 0.003). In SLE patients, EA/D reactivity was associated with Raynaud’s phenomenon and the presence of any anti-ENA antibodies. Although it did not reach a statistical significance, anti-EBNA-1 reactivity was slightly lower in patients with SLE. The frequency of anti-CMV Ig G positivity was found significantly higher in SLE patients (100%) when compared to patients with SSc (95.7%), PAPS (94.7%) and healthy controls (95.4%) (P = 0.035, P = 0.025 and P = 0.015 respectively). Our results support the proposed link between EBV and SLE. The finding that SSc and PAPS patients also have increased frequency of anti-EA/D response has revealed that this immune interaction may not be unique to patients with SLE, and there may be a common mechanism involving EBV in these autoimmune diseases.
Similar content being viewed by others
References
Sabbatini A, Bombardieri S, Migliorini P (1993) Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I. Eur J Immunol 23:1146–1152
James JA, Harley JB (1992) Linear epitope mapping of an Sm B/B’ polypeptide. J Immunol 148:2074–2079
Cohen JI (2000) Epstein-Barr virus infection. N Engl J Med 343:481–492
Linde A (2002) Epstein-Barr Virus. In: Richman DD, Whitley RJ, Hayden FG (eds) Clinical virology. ASM, Washington DC, pp 1331–1340
Sumaya CV, Ench E (1985) Epstein-Barr virus infection mononucleosis in children. II. Heterophile antibodies and viral-specific responses. Pediatrics 75(6):1011–1019
Tsai YT, Chiang BL, Kao YF, Hsieh KH (1995) Detection of Epstein-Barr virus and cytomegalovirus genome in white blood cells from patients with juvenile rheumatoid arthritis and childhood systemic lupus erythematosus. Int Arch Allergy Immunol 106:235–240
James JA, Kaufman KM, Farris AD, Taylor-Albert E, Lehman TA, Harley JB (1997) An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 100:3019–3026
James JA, Neas BN, Moser KL et al (2001) Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 44:1122–1126
Huggins ML, Todd I, Powell RJ (2005) Reactivation of Epstein-Barr virus in patients with systemic lupus erythematosus. Rheumatol Int 25(3):183–187
Lau CS, Yuen KY, Chan KH, Wong RW (1998) Lack of evidence of active lytic replication of Epstein-Barr and cytomegaloviruses in patients with systemic lupus erythematosus. Chin Med J (Engl) 111:660–665
Incaprera M, Rindi L, Bazzichi A, Garzelli C (1998) Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol 16:289–294
Yu S, Wu HC, Tsai W et al (2004) Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with SLE. Med Microbiol Immunol 194:115–120
Moon UY, Park SJ, Oh ST et al (2004) Patients with SLE have abnormally elevated EBV load in blood. Arthritis Res Ther 6:295–302
Chen CJ, Lin KH, Lin SC et al (2005) High prevalance of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies. J Rheumatol 32(1):44–47
Casciola-Rosen LA, Anhalt G, Rosen A (1994) Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179:1317–1330
Tsokos GC, Magrath GC, Balow JE (1983) Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol 131:1797–1801
Kang I, Quan T, Nolasco H et al (2004) Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 172:1287–1294
Parks CG, Cooper GS, Hudson LL et al (2005) Association of Epstein-Barr virus with systemic lupus erythematosus. Arthritis Rheum 52(4):1148–1159
Horwitz DA, Stohl W, Gray JD (2003) Cytokines in the pathogenesis of systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 6th edn. Lippincott Williams & Wilkins, Philadelphia, p 197
Abbas AK, Lichtman AH (2003) Cytokines. In: Abbas AK, Lichtman AH (eds) Cellular and molecular immunology, 5th edn. Saunders, Philadelphia, pp 261–263
Pender MP (2003) Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol 24:584–588
Sabbatini A, Bombardieri S, Migliorini P (1993) Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA-1. Eur J Immunol 23:1146–1152
James JA, Harley JB (1992) Linear epitope mapping of an Sm B/B’ polypeptide. J Immunol 148:2074–2079
McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley J, James JA (2005) Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 11(1):85–89
Arbuckle MR, McClain MT, Rubertone MV et al (2003) Autoantibodies are present years before the clinical onset of systemic lupus erythematosus. N Engl J Med 349(16):1526–1533
Kahan A, Kahan A, Menkes CJ, Amor B (1986) Defective Epstein-Barr virus specific suppressor T cell function in progressive systemic sclerosis. Ann Rheum Dis 45(7):553–560
Zandman-Goddard G, Berkun Y, Barzilai O, Boaz M, Blank M, Ram M, Sherer Y, Anaya JM, Shoenfeld Y (2009) Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann NY Acad Sci 1173:658–663
Rider JR, Ollier WER, Lock RJ, Brookes ST, Pamphilon DH (1997) Human cytomegalovirus infection and systemic lupus erythematosus. Clin Exp Rheumatol 15:405–409
Acknowledgments
This study was supported by The Society for Education and Research in Rheumatology (RAED-Turkey).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Esen, B.A., Yılmaz, G., Uzun, S. et al. Serologic response to Epstein-Barr virus antigens in patients with systemic lupus erythematosus: a controlled study. Rheumatol Int 32, 79–83 (2012). https://doi.org/10.1007/s00296-010-1573-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-010-1573-4